About: Enhanced Intrapulmonary Delivery of Anticancer siRNA for Lung Cancer Therapy Using Cationic Ethylphosphocholine-based Nanolipoplexes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Enhanced Intrapulmonary Delivery of Anticancer siRNA for Lung Cancer Therapy Using Cationic Ethylphosphocholine-based Nanolipoplexes Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Enhanced Intrapulmonary Delivery of Anticancer siRNA for Lung Cancer Therapy Using Cationic Ethylphosphocholine-based Nanolipoplexes
Creator	Oh, Yu-Kyoung Yu, Yong Kim, Chan-Wha Choi, Junhyeok Choi, Yongseok Lee, Sangbin Park, Da-Eui Shim, Gayong Choi, Hyun-Woo
Source	Elsevier; Medline; PMC
abstract	Here, we report a cationic nanolipoplex as a pulmonary cellular delivery system for small-interfering RNA (siRNA). Six nanoliposomes differing in cationic lipids were formulated and screened in vitro and in vivo for cellular delivery functions in lung cells/tissues. Although the six nanoliposomes showed similar siRNA delivery efficiency in vitro, they exhibited significant differences in pulmonary cellular delivery functions in vivo. Among the various nanoliposomes, cationic dioleoyl-sn-glycero-3-ethylphosphocholine and cholesterol (ECL)-based nanoliposomes showed the highest pulmonary cellular delivery in vivo and the lowest cytotoxicity in vitro. The delivery efficiency of fluorescent siRNA in ECL nanoliposomes was 26.2-fold higher than that of naked siRNA in vivo. Treatment with Mcl1 (myeloid cell leukemia sequence 1)-specific siRNA (siMcl1) using ECL nanolipoplexes reduced target expression in B16F10 cell lines, whereas control, luciferase-specific siGL2 in ECL nanolipoplexes did not. In metastatic lung cancer mouse models induced by B16F10 or Lewis lung carcinoma (LLC) cells, intratracheal administration of siMcl1 in ECL nanolipoplexes significantly silenced Mcl1 mRNA and protein levels in lung tissue. Reduced formation of melanoma tumor nodules was observed in the lung. These results demonstrate the utility of ECL nanoliposomes for pulmonary delivery of therapeutic siRNA for the treatment of lung cancers and potentially for other respiratory diseases.
has issue date	2013-04-01(xsd:dateTime)
bibo:doi	10.1038/mt.2013.10
bibo:pmid	23380818
has license	hybrid-oa
sha1sum (hex)	d4b69ab9cf2532659e1e48964722abc74985bddf
schema:url	https://doi.org/10.1038/mt.2013.10
resource representing a document's title	Enhanced Intrapulmonary Delivery of Anticancer siRNA for Lung Cancer Therapy Using Cationic Ethylphosphocholine-based Nanolipoplexes
has PubMed Central identifier	PMC3616525
has PubMed identifier	23380818
schema:publication	Molecular Therapy
resource representing a document's body	covid:d4b69ab9cf2532659e1e48964722abc74985bddf#body_text
is schema:about of	named entity 'SIRNA' named entity 'lung' named entity 'vivo' named entity 'cellular' named entity 'functions' named entity 'vivo' named entity 'The delivery' named entity 'melanoma' named entity 'ECL' named entity 'Here' named entity 'NODULES' named entity 'DID' named entity 'CHOLESTEROL' named entity 'LUNG CANCERS' named entity 'REPORT' named entity 'RESULTS' named entity 'OBSERVED' named entity 'CELL' named entity 'DELIVERY' named entity 'UTILITY' named entity 'MRNA' named entity 'B16F10 CELL' named entity 'HIGHEST' named entity 'THESE' named entity 'MOUSE MODELS' named entity 'MELANOMA' named entity 'SILENCED' named entity 'HERE' named entity 'FLUORESCENT' named entity 'LUNG TISSUE' named entity 'TREATMENT' named entity 'LEUKEMIA' named entity 'METASTATIC LUNG CANCER' named entity 'SIGNIFICANT' named entity 'LUCIFERASE' named entity 'HIGHER' named entity 'SPECIFIC' named entity 'LIPIDS' named entity 'DELIVERY SYSTEM' named entity 'USING' named entity 'CONTROL' named entity 'RESPIRATORY DISEASES' named entity 'VARIOUS' named entity 'LOWEST' named entity 'LUNG' named entity 'B16F10' named entity 'CELLS' named entity 'INTRATRACHEAL ADMINISTRATION' named entity 'INDUCED' named entity 'THERAPEUTIC' named entity 'IN VIVO' named entity 'SIRNA' named entity 'EFFICIENCY' named entity 'SEQUENCE' named entity 'PULMONARY' named entity 'PROTEIN LEVELS' named entity 'CELLULAR' named entity 'NAKED' named entity 'DELIVERY' named entity 'LEWIS LUNG CARCINOMA' named entity 'CELL LINES' named entity 'LUNG' named entity 'BASED' named entity 'CYTOTOXICITY IN VITRO' named entity 'IN VITRO' named entity 'REDUCED' named entity 'TARGET' named entity 'INTERFERING RNA' named entity 'MCL1' named entity 'TUMOR' named entity 'FORMATION' named entity 'FOLD' named entity 'SMALL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software